

prevention, and control of nosocomial infections in U.S. hospitals and updating of guidelines and other policy statements regarding prevention of nosocomial infections.

Matters To Be Discussed: The agenda will include review and discussion of public comments regarding the draft Guideline for the Prevention of Nosocomial Intravascular Device-Related Infections, review of the first draft of the Guideline for Infection Control in Hospital Personnel, and an update on CDC activities of interest to the Committee. Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Julia S. Garner, Nurse Consultant, Hospital Infections Program, NCID, CDC, 1600 Clifton Road, NE, Mailstop A-07, Atlanta, Georgia 30333, telephone 404/639-6408.

Dated: October 17, 1995.

Julia M. Fuller,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-26146 Filed 10-20-95; 8:45 am]

BILLING CODE 4163-18-M

Advisory Committee for Injury Prevention and Control (ACIPC) and the Science and Program Review Work Group; Meetings

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meetings.

Name: Science and Program Review Work Group.

Time and Date: 1 p.m.-4 p.m., November 13, 1995.

Place: National Center for Injury Prevention and Control (NCIPC), Vanderbilt Building, Conference Room 1004, 2939 Flowers Road, South, Chamblee, Georgia 30341.

Status: Open to the public, limited only by the space available.

Purpose: The purpose of this work is to advise NCIPC on program and scientific activities.

Matters To Be Discussed: The Work Group will discuss future grant program announcements and Ad Hoc committee reports.

Agenda items are subject to change as priorities dictate.

Name: Advisory Committee for Injury Prevention and Control (ACIPC).

Time and Date: 9 a.m.-3:30 p.m., November 14, 1995.

Place: Holiday Inn at Lenox, 3377 Peachtree Road, NE, Atlanta, Georgia 30326.

Status: Open to the public, limited only by the space available.

Purpose: The Committee will continue to make recommendations on policy, strategy, objectives, and priorities including the balance and mix of intramural and extramural research; advise on the implementation of a national plan for injury

prevention and control, the development of new technologies and their application; and review progress toward injury prevention and control.

Matters To Be Discussed: The Committee will meet to discuss (1) current and future issues in violence prevention, (2) reports from other agencies on violence prevention activities, (3) an update from the Director, NCIPC, and (4) a report of the Science and Program Review Work Group and the Family and Intimate Violence Prevention Subcommittee meeting, held in Des Moines, Iowa.

Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Mr. Thomas A. Bartenfeld, Acting Executive Secretary, ACIPC, NCIPC, Mailstop K-60, CDC, 4770 Buford Highway, NE, Atlanta, Georgia 30341-3724, telephone 770/488-4230.

Dated: October 17, 1995.

Julia M. Fuller,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-26145 Filed 10-20-95; 8:45 am]

BILLING CODE 4163-18-M

CDC Advisory Committee on the Prevention of HIV Infection; Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: CDC Advisory Committee on the Prevention of HIV Infection.

Times and Dates: 8:30 a.m.-5 p.m., November 13, 1995; 8:30 a.m.-3 p.m., November 14, 1995.

Place: Corporate Square Office Park, Corporate Square Boulevard, Building 11, Room 1413, Atlanta, Georgia 30329.

Status: Open to the public, limited only by the space available.

Purpose: This committee is charged with advising the Director, CDC, regarding objectives, strategies, and priorities for HIV prevention efforts including maintaining surveillance of HIV infection and AIDS, the epidemiologic and laboratory study of HIV and AIDS, information/education and risk reduction activities designed to prevent the spread of HIV infection, and other preventive measures that become available.

Matters To Be Discussed: The Committee will be updated on the ongoing reorganization of CDC's HIV/AIDS prevention programs. Other discussions will center around current HIV prevention activities. Agenda items are subject to change as priorities dictate.

Contact Person For More Information: Connie Granoff, Committee Management Specialist, National Center for HIV, STD, and TB Prevention (proposed), 1600 Clifton Road, NE, Mailstop E-07, Atlanta, Georgia 30333, telephone (404) 639-8029.

Dated: October 17, 1995.

Julia M. Fuller,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95-26147 Filed 10-20-95; 8:45 am]

BILLING CODE 4163-18-M

Food and Drug Administration

[Docket No. 95C-0399]

United States Surgical Corp.; Filing of Color Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that United States Surgical Corp. has filed a petition proposing that the color additive regulations be amended to provide for the safe use of D&C Violet No. 2 as a color additive in glycolide/dioxanone/trimethylene carbonate tripolymer absorbable sutures for general surgery.

DATES: Written comments on the petitioner's environmental assessment by November 22, 1995.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857. **FOR FURTHER INFORMATION CONTACT:** Ellen M. Waldron, Center for Food Safety and Applied Nutrition (HFS-216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-606-0202.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 721(d)(1) (21 U.S.C. 379e(d)(1))), notice is given that a color additive petition (CAP 5C0248) has been filed by United States Surgical Corp., 150 Glover Ave., Norwalk, CT 06856. The petition proposes to amend the color additive regulations in § 74.3602 *D&C Violet No. 2* (21 CFR 74.3602) to provide for the safe use of D&C Violet No. 2 as a color additive in glycolide/dioxanone/trimethylene carbonate tripolymer absorbable sutures for general surgery.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4 (b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for

public review and comment. Interested persons may, on or before November 22, 1995, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the Federal Register. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the Federal Register in accordance with 21 CFR 25.40(c).

Dated: October 10, 1995.

Alan M. Rulis,

Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.

[FR Doc. 95-26153 Filed 10-20-95; 8:45 am]

BILLING CODE 4160-01-F

National Institutes of Health

Prospective Grant of Exclusive License: Melanoma Antigens and Their Use in Diagnostic and Therapeutic Methods

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the invention embodied in U.S. Patent Application Serial Number 08/231,565, entitled "Melanoma Antigens and Their Use in Diagnostic and Therapeutic Methods" and related foreign patent applications to Therion Biologics Corporation, of Cambridge, Massachusetts. The patent rights in this invention have been assigned to the United States of America.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. This license will be limited to the field of treatment and/

or prevention of cancer in humans using recombinant poxviruses comprising melanoma antigens. The melanoma antigens may be limited to MART-1 and gp100, encoded by Sequence ID Nos. 1 and 26 (described in patent application 08/231,565), respectively, and fragments thereof. This prospective exclusive license may be granted unless within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The patent application describes nucleic acid sequences that encode novel melanoma antigens MART-1 and gp100, recombinant protein MART-1 and gp100, peptides from MART-1 and gp100 which react with tumor infiltrating lymphocytes (TIL cells), and recombinant expression vectors comprising nucleic acids that encode MART-1 or gp100, and fragments thereof.

ADDRESSES: Requests for a copy of this patent application (which require a signed confidential disclosure agreement), inquiries, comments and other materials relating to the contemplated license should be directed to: Raphe Kantor, Ph.D., Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852; Telephone: 301/496-7735, ext 247; Facsimile: 301/402-0220. Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by NIH on or before December 22, 1995 will be considered. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: October 11, 1995.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 95-26189 Filed 10-20-95; 8:45 am]

BILLING CODE 4140-01-P

Public Health Service

National Center for Health Statistics; the ICD-9-CM Coordination and Maintenance Committee; Notice

AGENCY: National Center for Health Statistics, DHHS.

ACTION: Notice of meeting.

SUMMARY: The ICD-9-CM Coordination and Maintenance Committee (C&M) will be holding its final meeting of the year on Thursday, November 30, 1995. The C&M meeting is a public forum for the presentation of proposed modifications to the International Classification of Diseases, ninth-revision, clinical modification.

DATES: The meeting will be held on November 30, 1995 from 9 a.m.-5 p.m.

ADDRESS: The Hubert H. Humphrey building, rm. 703A, 200 Independence Ave. Washington, D.C.

NOTICE: In the interest of security, the Humphrey building has instituted stringent procedures for entrance into the building by non-government employees. Persons without a government I.D. will need to show a photo I.D., sign-in, and be escorted up to the meeting room. Please arrive prior to the 9 a.m. start time of the meeting to assure an escort will be available. Entrance to the meeting after 9 a.m. cannot be assured.

FOR FURTHER INFORMATION CONTACT: Amy Blum 301-436-4216.

SUPPLEMENTARY INFORMATION:

Tentative Agenda

Child/Adult Abuse

Factitious Disorder by Proxy

Mental Health Disorders

Immunization V codes

External Cause of Injury

Development of ICD-10 Procedure Classification

Noncoronary stents

Endometrial ablation

Pancreatic islet cell transplant

Laparoscopic/thoroscopic procedures

Addenda

Sue Meads,

R.R.A., Co-chair, ICD-9-CM Coordination and Maintenance Committee.

[FR Doc. 95-26093 Filed 10-20-95; 8:45 am]

BILLING CODE 4160-18-M

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

Office of the Secretary

[Docket No. FR-3926-D-01]

Designating Attesting Officers

AGENCY: Office of the Secretary, HUD.

ACTION: Delegation of authority to cause department seal to be affixed and to authenticate copies of documents.

SUMMARY: This delegation of authority revises and updates the designation of attesting officers to authenticate documents.